Basil Drugs And Pharmaceuticals Private Limited - Company Profile

It is a pharma private limited company based in Mumbai, Maharashtra, India, established in 2018.
2018 Mumbai, Maharashtra, India Active
Last Updated:
Access Report
About Basil Drugs And Pharmaceuticals Private Limited

Basil Drugs And Pharmaceuticals Private Limited, a active private limited company, was established on 24 January 2018 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24303MH2018PTC304632. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹8.00 M and a paid-up capital of ₹5.50 M.

Employing 20 professional, Its leadership includes Priyamvada Anup Singh (Director), Anup Dinesh Singh (Director), Punit Girdhar Kasat (Director). Past directors included Mudrika Shivshankar Banger, Shivshankar Gangaram Bangar, Punit Girdhar Kasat. It holds ₹10.28 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at A 609 Sagar Tech Plaza Andheri Kurla Rd Sakinaka Junction Andheri (E), Mumbai, Maharashtra, 400072.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24303MH2018PTC304632

  • Registration Number

    304632

  • Incorporation Date

    24 January 2018

  • Authorized Capital

    ₹8.00 M

  • Paid-Up Capital

    ₹5.50 M

  • ROC Code

    Roc Mumbai

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 8.00 M
  • Paid Up Capital ₹ 5.50 M
  • Company Age 8 Year, 2 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 10.28 Cr
  • Revenue Growth **** -31.56%
  • Profit Growth **** -53.28%
  • Ebitda **** -17.70%
  • Net Worth 387.80%
  • Total Assets **** 62.44%
Company report

Basil Drugs And Pharmaceuticals Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Basil Drugs And Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Basil Drugs And Pharmaceuticals Private Limited?
Current Directors
Name Designation Appointment Date Status
Priyamvada Anup Singh Director 24 Jan 2018 Current
Anup Dinesh Singh Director 24 Jan 2018 Current
Punit Girdhar Kasat Director 10 Jun 2025 Current
Finil Bharat Pandya Director 10 Jun 2025 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 10 Jul 2023 Past
Pramod Abcsdd Director 10 Jul 2023 Past
Pramod Abcsdd Additional Director 29 Sep 2025 Past
Pramod Abcsdd Additional Director 17 Feb 2024 Past
Pramod Abcsdd Additional Director 29 Sep 2025 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Basil Drugs And Pharmaceuticals.

Basil Drugs And Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 31.56% decrease. The company also saw a substantial fall in profitability, with a 53.28% decrease in profit. The company's net worth Soared by an impressive increase of 387.8%.

Basil Drugs And Pharmaceuticals revenue growth over time
Basil Drugs And Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 -31.56%
*******
*******
*******
*******
Revenue from Operations
*******
 -31.39%
*******
*******
*******
*******
Total Assets
*******
 62.44%
*******
*******
*******
*******
Profit or Loss
*******
 -53.28%
*******
*******
*******
*******
Net Worth
*******
 387.80%
*******
*******
*******
*******
EBITDA
*******
 -17.70%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Basil Drugs And Pharmaceuticals?

In 2023, Basil Drugs And Pharmaceuticals had a public holding of 22.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹102,830,000.00

Satisfied Charges

₹0

Charges Breakdown by Lending Institutions
  • Canara Bank : 5.00 Cr
  • State Bank Of India : 4.99 Cr
  • Hdfc Bank Limited : 0.29 Cr
Latest Charge Details
Date Lender Amount Status
17 Jun 2025 Canara Bank ₹5.00 Cr Open
27 Mar 2024 State Bank Of India ₹4.99 Cr Open
20 May 2022 Hdfc Bank Limited ₹0.49 M Open
20 May 2022 Hdfc Bank Limited ₹0.98 M Open
12 May 2022 Hdfc Bank Limited ₹0.49 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Basil Drugs And Pharmaceuticals?

Basil Drugs And Pharmaceuticals has a workforce of 20 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Basil Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Basil Drugs And Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Basil Drugs And Pharmaceuticals
Recent Activity within the Organization
  • Annual General Meeting

    Progress on Basil Drugs And Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.

  • Charges

    Progress on A charge with Canara Bank amounted to Rs. 50.00 M with Charge ID 101119968 was registered on 17 Jun 2025. was documented.

  • Director Appointment

    Progress on Punit Girdhar Kasat was appointed as a Director was appointed as a Director on 10 Jun 2025 & has been associated with this company since 9 months 18 days . was documented.

  • Director Appointment

    The activity Finil Bharat Pandya was appointed as a Director was appointed as a Director on 10 Jun 2025 & has been associated with this company since 9 months 18 days . was completed.

  • Balance Sheet

    Basil Drugs And Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was recorded as a recent event.

  • Charges

    The activity A charge with State Bank Of India amounted to Rs. 49.90 M with Charge ID 100895209 was registered on 27 Mar 2024. was completed.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Basil Drugs And Pharmaceuticals Private Limited?

The CIN of Basil Drugs And Pharmaceuticals Private Limited is U24303MH2018PTC304632.

Where is Basil Drugs And Pharmaceuticals Private Limited headquartered?

Basil Drugs And Pharmaceuticals Private Limited is headquartered at A 609 Sagar Tech Plaza Andheri Kurla Rd Sakinaka Junction Andheri (E), Mumbai, Maharashtra, 400072.

When was Basil Drugs And Pharmaceuticals Private Limited incorporated?

Basil Drugs And Pharmaceuticals Private Limited was incorporated on 24 January 2018.

Who are the current directors of Basil Drugs And Pharmaceuticals Private Limited?

The current directors of Basil Drugs And Pharmaceuticals Private Limited are

What is the primary industry of Basil Drugs And Pharmaceuticals Private Limited?

The primary industry of Basil Drugs And Pharmaceuticals Private Limited is Manufacturing.

Is Basil Drugs And Pharmaceuticals Private Limited a listed company?

Basil Drugs And Pharmaceuticals Private Limited is unlisted.

What is the capital structure of Basil Drugs And Pharmaceuticals Private Limited?

The authorized capital of Basil Drugs And Pharmaceuticals Private Limited is ₹8.00 M, and the paid-up capital is ₹5.50 M.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available